---
layout: default
title: Ganirelix
parent: Model Prediction Only (L5)
nav_order: 423
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ganirelix: From Preventing Premature LH Surges in Assisted Reproduction to Hypertrichosis

## One-Sentence Summary

Ganirelix is a GnRH antagonist used to prevent premature LH surges during ovarian stimulation in assisted reproduction.
The TxGNN model predicts it may be effective for **hypertrichosis** with a very high score, but there are currently **0 clinical trials** and **0 relevant publications** supporting this direction. This is a model-only prediction, and its mechanistic basis is weak.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Inhibition of premature LH surges in assisted reproduction (from the drug's known use; the Canadian licence record contains no indication text) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the Evidence Pack. Ganirelix is known to be a GnRH receptor antagonist. It blocks the pituitary GnRH receptor, which rapidly suppresses LH and FSH and, downstream, gonadal sex steroids.

**For hypertrichosis, the mechanistic link is weak.** Hypertrichosis is usually caused by genetic, drug-induced or metabolic factors, not by GnRH signalling. The high score (99.98%) reflects the model's knowledge-graph neighbourhood, not clinical or literature evidence.

The same applies to the other hair-related predictions (Ambras type hypertrichosis universalis congenita, isolated genetic hair shaft abnormality, familial isolated trichomegaly). These are genetic structural conditions that a GnRH antagonist would not be expected to modify.

Among the ten predictions, **central precocious puberty** (rank 9) is the most biologically coherent. It is driven by early activation of the hypothalamic-pituitary-gonadal axis, which GnRH antagonism directly targets. However, the standard of care is long-acting GnRH agonists. Ganirelix is a short-acting injectable, and any advantage over the agonists has not been studied.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

A different prediction (rank 3, malformation syndrome with a periodontal component) returned 20 publications. They are general periodontitis papers (guidelines, reviews, diabetes associations) that do not mention ganirelix. They reflect keyword matching on the disease term and are not drug-specific evidence.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2245641 | ORGALUTRAN |

Dosage form, manufacturer and approved indication text are not recorded in the licence data.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top prediction (hypertrichosis) is supported only by the model score, with no trials, no drug-specific literature and no plausible mechanism (Evidence Level L5). Within the prediction list, central precocious puberty is the only candidate worth a mechanistic research question.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the Canadian licence
- A targeted literature and trial search for ganirelix in central precocious puberty, including comparison against GnRH agonists
- Route and formulation compatibility assessment for any chronic-use indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

